Estimating the effects of patient-reported outcome (PRO) diarrhea and pain measures on PRO fatigue: Data analysis from a phase II study of abemaciclib monotherapy, a CDK4 and CDK6 inhibitor, in patients with HR+/HER2-breast cancer after chemotherapy for metastatic disease-MONARCH 1

Category Primary study
JournalJournal of Clinical Oncology
Year 2017
This article has no abstract
Epistemonikos ID: 23a717f00b95f450afa831df82f15622bbd60f1f
First added on: Feb 08, 2025